Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 3/20 | 0.32 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.30 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3360468 | 0.79 | RXRA (0.34) | KDM4ENPC1MAPTRAB9AAKT1 | |
| SCHEMBL3515054 | 0.77 | GHSR (0.36) | KDM4ENPC1MAPTRAB9AAKT1 | |
| SCHEMBL3361228 | 0.76 | GAA (0.38) | KDM4ENPC1MAPTRAB9AAKT1 | |
| SCHEMBL12987017 | 0.75 | MT-CO2 (0.38) | KDM4ENPC1MAPTRAB9AAKT1 | |
| SCHEMBL31472213 | 0.75 | MT-CO2 (0.38) | KDM4ENPC1MAPTRAB9AAKT1 | |
| SCHEMBL3361225 | 0.75 | AKT1 (0.33) | KDM4ENPC1MAPTRAB9AAKT1 | |
| SCHEMBL28420950 | 0.73 | MIF (0.46) | KDM4ENPC1MAPTRAB9AAKT1 | |
| SCHEMBL10565261 | 0.72 | NOX1 (0.46) | KDM4ENPC1MAPTRAB9AAKT1 | |
| SCHEMBL14108121 | 0.72 | RAB9A (0.41) | NPC1MAPTRAB9AAKT1 | |
| SCHEMBL4199655 | 0.72 | CA12 (0.38) | KDM4ENPC1MAPTRAB9AAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120762-B2 | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-09-01 | — | — | US | disclosed |
| EP-2236500-B1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2014-12-24 | — | — | EP | disclosed |
| US-20140140953-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2014-05-22 | — | — | US | disclosed |
| US-8642637-B2 | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-02-04 | — | — | US | disclosed |
| US-20120164102-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
| EP-2441457-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-04-18 | — | — | EP | disclosed |
| EP-2236500-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140140953-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | THPO, MPL, TEK | KDM4E 4321/4885NPC1 4311/4885MAPT 3465/4885 |
| US-20120164102-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | THPO, MPL, TEK | KDM4E 4321/4885NPC1 4311/4885MAPT 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.